Morepen Laboratories

Morepen Laboratories reported a net profit of Rs 30.47 crore on a consolidated basis in the April-June quarter of the financial year 2021-22, while its share price gained around 3 per cent

Morepen Laboratories has started production of the test batch of Russia's Sputnik V COVID-19 vaccine at its facility in Himachal Pradesh, Russian Direct Investment Fund (RDIF) and the domestic drug firm said in a statement on Tuesday.

Morepen Laboratories shares surged as much as 11per cent on Friday on a report that the Delhi-based pharma company is in talks to sell its OTC (over-the-counter) business.

Morepen Laboratories Ltd has informed BSE that in the 26th Annual General Meeting of the Company which was held on September 16, 2011, the resolutions in respect of the following have been approved by the shareholders:<p><p>1. Adoption of Annual Accounts, Directors Report and Auditors Report thereon for the financial year 2010-2011.<...

Morepen Laboratories Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from September 13, 2011 to September 16, 2011 (both days inclusive) for the purpose of Annual General Meeting (AGM) of the Company.

Sales rise 25.40% to Rs 52.68 croreMorepen Laboratories reported net loss of Rs 6.88 crore in the quarter ended March 2010 as against net profit of Rs 2.86 crore during the previous quarter ended March 2009. Sales rose 25.40% to Rs 52.68 crore in the quarter ended March 2010 as against Rs 42.01 crore during the previous quarter ended March 2009.For...

Sales rise 19.40% to Rs 57.55 croreMorepen Laboratories reported net profit of Rs 26.23 crore in the quarter ended September 2009 as against net loss of Rs 15.66 crore during the previous quarter ended September 2008. Sales rose 19.40% to Rs 57.55 crore in the quarter ended September 2009 as against Rs 48.20 crore during the previous quarter ended ...

Sales decline 13.58% to Rs 41.82 croreMorepen Laboratories reported net loss of Rs 10.90 crore in the quarter ended December 2009 as against net loss of Rs 13.47 crore during the previous quarter ended December 2008. Sales declined 13.58% to Rs 41.82 crore in the quarter ended December 2009 as against Rs 48.39 crore during the previous quarter ende...

The board of Morepen Laboratories has made an allotment of 9,24,90,413 equity shares of Rs 2 each to the fixed deposit holders of the company. These shares have been allotted at a price of Rs 11.32 per share pursuant to the order dated 04 August 2009 of the Hon'ble High Court of Himachal Pradesh at Shimla approving the scheme of compromise and arra...

Morepen Laboratories reported net loss of Rs 10.20 crore in the quarter ended June 2009 as against net loss of Rs 10.58 crore during the previous quarter ended June 2008. Sales rose 10.75% to Rs 42.55 crore in the quarter ended June 2009 as against Rs 38.42 crore during the previous quarter ended June 2008. ParticularsQuarter Ended Jun. 2009Jun. 2...

The board meeting of Morepen Laboratories will be held 12 August 2009 to make the allotment of equity shares of Rs 2 each, pursuant to a scheme of compromise or arrangement approved on 04 August 2009 by the Hon'ble High Court of Himachal Pradesh to the fixed deposit holders of the company.

Morepen Laboratories reported net profit of Rs 2.86 crore in the quarter ended March 2009 as against net loss of Rs 0.76 crore during the previous quarter ended March 2008. Sales rose 22.98% to Rs 42.01 crore in the quarter ended March 2009 as against Rs 34.16 crore during the previous quarter ended March 2008.For the full year, net loss reported t...

Morepen Laboratories Limited has informed the Exchange that the Company has decided to submit audited financial results for the entire financial year within 60 days of the end of the financial year instead to submit un- audited financial results along with the limited review report within 45 days.

Morepen Laboratories Ltd has informed BSE that the members at the 25th Annual General Meeting (AGM) of the Company held on September 17, 2010, have approved the following resolutions:  1. Adoption of Annual Accounts, Directors Report and Auditors Report thereon for the financial year 2009-2010.  2. Re-appointment of Mr. Sukhcharan Singh w...

Morepen Laboratories reported a net profit of Rs 30.47 crore on a consolidated basis in the April-June quarter of the financial year 2021-22, while its share price gained around 3 per cent

Morepen Laboratories has started production of the test batch of Russia's Sputnik V COVID-19 vaccine at its facility in Himachal Pradesh, Russian Direct Investment Fund (RDIF) and the domestic drug firm said in a statement on Tuesday.

Morepen Laboratories shares surged as much as 11per cent on Friday on a report that the Delhi-based pharma company is in talks to sell its OTC (over-the-counter) business.

Morepen Laboratories Ltd has informed BSE that in the 26th Annual General Meeting of the Company which was held on September 16, 2011, the resolutions in respect of the following have been approved by the shareholders:<p><p>1. Adoption of Annual Accounts, Directors Report and Auditors Report thereon for the financial year 2010-2011.<...

Morepen Laboratories Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from September 13, 2011 to September 16, 2011 (both days inclusive) for the purpose of Annual General Meeting (AGM) of the Company.

Sales rise 25.40% to Rs 52.68 croreMorepen Laboratories reported net loss of Rs 6.88 crore in the quarter ended March 2010 as against net profit of Rs 2.86 crore during the previous quarter ended March 2009. Sales rose 25.40% to Rs 52.68 crore in the quarter ended March 2010 as against Rs 42.01 crore during the previous quarter ended March 2009.For...

Sales rise 19.40% to Rs 57.55 croreMorepen Laboratories reported net profit of Rs 26.23 crore in the quarter ended September 2009 as against net loss of Rs 15.66 crore during the previous quarter ended September 2008. Sales rose 19.40% to Rs 57.55 crore in the quarter ended September 2009 as against Rs 48.20 crore during the previous quarter ended ...

Sales decline 13.58% to Rs 41.82 croreMorepen Laboratories reported net loss of Rs 10.90 crore in the quarter ended December 2009 as against net loss of Rs 13.47 crore during the previous quarter ended December 2008. Sales declined 13.58% to Rs 41.82 crore in the quarter ended December 2009 as against Rs 48.39 crore during the previous quarter ende...

The board of Morepen Laboratories has made an allotment of 9,24,90,413 equity shares of Rs 2 each to the fixed deposit holders of the company. These shares have been allotted at a price of Rs 11.32 per share pursuant to the order dated 04 August 2009 of the Hon'ble High Court of Himachal Pradesh at Shimla approving the scheme of compromise and arra...

Morepen Laboratories reported net loss of Rs 10.20 crore in the quarter ended June 2009 as against net loss of Rs 10.58 crore during the previous quarter ended June 2008. Sales rose 10.75% to Rs 42.55 crore in the quarter ended June 2009 as against Rs 38.42 crore during the previous quarter ended June 2008. ParticularsQuarter Ended Jun. 2009Jun. 2...

The board meeting of Morepen Laboratories will be held 12 August 2009 to make the allotment of equity shares of Rs 2 each, pursuant to a scheme of compromise or arrangement approved on 04 August 2009 by the Hon'ble High Court of Himachal Pradesh to the fixed deposit holders of the company.

Morepen Laboratories reported net profit of Rs 2.86 crore in the quarter ended March 2009 as against net loss of Rs 0.76 crore during the previous quarter ended March 2008. Sales rose 22.98% to Rs 42.01 crore in the quarter ended March 2009 as against Rs 34.16 crore during the previous quarter ended March 2008.For the full year, net loss reported t...

Morepen Laboratories Limited has informed the Exchange that the Company has decided to submit audited financial results for the entire financial year within 60 days of the end of the financial year instead to submit un- audited financial results along with the limited review report within 45 days.

Morepen Laboratories Ltd has informed BSE that the members at the 25th Annual General Meeting (AGM) of the Company held on September 17, 2010, have approved the following resolutions:  1. Adoption of Annual Accounts, Directors Report and Auditors Report thereon for the financial year 2009-2010.  2. Re-appointment of Mr. Sukhcharan Singh w...